[Changes in lipoprotein spectrum in patients with the diagnosis of extremity vascular ischemic disease].
New method of lipoprotein determination on polyacrylamid gel with Lipoprint LDL system quantifies non atherogenic and atherogenic plasma lipoproteins, including small dense LDL, the potent atherogenic lipoprotein subpopulations. According to majority of non atherogenic versus atherogenic lipoprotein in the whole lipoprotein spectrum, this method distinguishes a non atherogenic lipoprotein profile phenotype A from an atherogenic lipoprotein profile phenotype B. Definitely, the contribution of this method is focusing on the atherogenic lipoprotein profile phenotype B in 80% of patients with an extremito-vascular ischemic disease and on the existence of control subgroup ofnormolipemic subjects with an atherogenic lipoprotein profile (7% ofprobands of control group). These persons represent a risk population. Till now, the facilities for identifying of these "normolipemic persons at risk" are limited.